HBEGF and cancer: Elevated expression of HB-EGF (an EGFR ligand) contributes to cancer cell resistance to paclitaxel, and shedding the extracellular domain of HB-EGF can induce sustained activation of JNK/p38 MAPK to overcome this resistance (113).